A Queensland pharmacy faces A$75,120 in penalties following allegations it unlawfully manufactured medicinal cannabis.
The Therapeutic Goods Administration (TGA) issued four infringement notices to Summit Pharmacy after conducting an inspection in August 2024.
The TGA said it found the business was "manufacturing medicinal cannabis oils in bulk amounts, in alleged contravention of the Therapeutic Goods Act 1989".
"The Act prohibits the manufacturing of therapeutic goods unless the goods are entered in the Australian Register of Therapeutic Goods or subject to an exemption, approval or authority," the regulator said in a statement.
"Individuals and businesses, including pharmacists and pharmacies, must ensure that they comply with all regulatory requirements prior to the manufacture and supply of compounded medicinal cannabis products."
The TGA website shows these are the first fines issued for medicinal cannabis infringements since July 2024.
The case is also an uncommon example of a pharmacy being penalised for alleged compounding breaches, despite longstanding concern about the practice among suppliers.
Summit Pharmacy, located in Caloundra, presents itself as Australia's "premier alternative therapy pharmacy", with its "natural therapy" options including a "free prescription".
